52 Results for 'Diagnostics Accelerator'
- Technologies (9)
- Collaborations (2)
- Team (0)
- News (14)
- Pages (0)
- Multimedia (27)
- Publications (0)
- Jobs (0)
- Events (0)
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Disease Diagnosis and Therapy
The Problem Infectious diseases have plagued humanity for millennia, and the pathogens that infect and sicken humans are constantly evolving. Severe infections can cause sepsis, a life-threatening condition in which a patient’s immune system overreacts to the infection. The body starts to attack itself, which can lead to tissue damage, organ failure, and death. Sepsis...
INSPECTR™: Direct-to-Consumer Molecular Diagnostic
INSPECTR™ is a molecular diagnostic platform that combines freeze-dried synthetic gene networks with cell-free expression systems to create novel biosensors that detect and report the presence of a target DNA or RNA molecule without the need for power or lab equipment. This technology was licensed by Wyss startup Sherlock Biosciences in 2019.
abbieSense: Anaphylaxis Diagnostic
The molecule histamine plays a primary role in the anaphylaxis reaction, which is a major cause of illness and death in people with severe allergies. Histamine is a very small molecule composed of only seventeen atoms, making it a challenging target to detect. To date, no diagnostic test exists that can measure histamine levels accurately...
Toehold Switches for Synthetic Biology
The burgeoning field of synthetic biology is designing artificial gene circuits that recognize molecules in their environment and respond by regulating genes with desired activities. In the future, such capabilities could allow the engineering of cells as diagnostic or therapeutic devices, factories for the production of clinically or industrially coveted molecules, and as specialized devices...
FISSEQ: Fluorescent In Situ Sequencing
Working copies of active genes — called messenger RNAs or mRNAs —translate the genetic information present in DNA into proteins within the cells’ multiple compartments. They are often positioned strategically within cells in ways that contribute critically to how cells and tissues grow, develop and function, and their mislocation can lead to disease development. To...
Over 15 million Americans are at risk of anaphylaxis, a severe allergic reaction triggered by exposure to certain foods, materials, medications, and insect bites. Every three minutes, a food reaction sends someone to the emergency room. In most individuals, anaphylactic shock can be prevented by administering the counteracting drug epinephrine, as soon as an attack...
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress the timeframe for bringing new, high-impact, diagnostic technologies to market.
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs.
Video/AnimationHow can we get diagnostics to patients faster?The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University
Video/AnimationReimagine the World – Volume 2 – Diagnostics AcceleratorTwo clinicians collaborating with the Wyss Diagnostics Accelerator (DxA), Lise Johnson and Craig Hersh, as well as two members of the Wyss DxA Industrial Partnership Program, Nell Meosky Luo and Andy Levin, share how they would Reimagine the World and the personal stories that fuel their passion for the work they are doing. Credit: Wyss...
Video/AnimationWyss Diagnostics Accelerator – The Industrial Participant ProgramThe Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University
Video/AnimationReimagining Health Equity: Wyss Diagnostics AcceleratorWith the Wyss Diagnostics Accelerator (DxA), we’re reimagining health equity by accelerating the development and deployment of needed diagnostics in all settings, particularly in low-resource settings, by fostering deep collaborations driven by unmet needs. Credit: Wyss Institute at Harvard University
Video/AnimationReimagining Diagnostics for His Mom: Pawan JollyPawan Jolly is a Senior Staff Scientist leading the Sensors team to help develop better diagnostics for various illnesses and allergies. He also serves as the technology lead for the Wyss Diagnostics Accelerator. In this video, he shares a heartfelt personal story about his mom who suffers from severe allergies and how he would Reimagine...
Video/Animation2021 Kabiller Prize in Nanoscience and NanomedicineDavid R. Walt, a Wyss Core Faculty member, member of the faculty at Harvard Medical School in the Department of Pathology, and a Howard Hughes Medical Institute Professor, is the winner of the 2021 Kabiller Prize in Nanoscience and Nanomedicine, the world’s largest monetary award for outstanding achievement in the field of nanotechnology and its...